1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Weight Loss

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Weight Loss in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abbas, N; Brevik, EM; Dahle, J; Heyerdahl, H; Mollatt, C	1

Other Studies

1 other study(ies) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Weight Loss

Article	Year
Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab. PloS one, 2012, Volume: 7, Issue:8 Topics: Animals; Antibodies, Monoclonal, Humanized; Autoradiography; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds, 1-Ring; Humans; Leukocyte Count; Mice; Mice, Nude; Organometallic Compounds; Ovarian Neoplasms; Receptor, ErbB-2; Survival Analysis; Time Factors; Trastuzumab; Tumor Burden; Weight Loss; Xenograft Model Antitumor Assays	2012

Article

Year

Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.

PloS one, 2012, Volume: 7, Issue:8

Topics: Animals; Antibodies, Monoclonal, Humanized; Autoradiography; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds, 1-Ring; Humans; Leukocyte Count; Mice; Mice, Nude; Organometallic Compounds; Ovarian Neoplasms; Receptor, ErbB-2; Survival Analysis; Time Factors; Trastuzumab; Tumor Burden; Weight Loss; Xenograft Model Antitumor Assays

2012